We're focused on delivering healing to those who need it most
Eliksa is a biotechnology company developing medicines for people with few other options. Our proprietary products use the regenerative properties in amniotic fluid and amniotic membrane to promote healing for a range of diseases. Each of our products and product candidates is processed in our proprietary cGMP regenerative medicine facility, creating a uniform acellular product that maintains the biological activity of key components.
OUR RESEARCH PIPELINE
Discover the regenerative properties of amniotic fluid and amniotic membrane
Our amniotic fluid-derived biologics are a novel, multi-target modulator of inflammation that promotes cell recovery and tissue healing. These proprietary biologics are derived from amniotic fluid recovered during routine cesarean section, and carefully processed under cGMP conditions to maintain biological activity of key components. Our product candidates are currently in clinical trials for multiple disease areas.
Amniotic Membrane Allograft
Our manufacturing technology uses proprietary cGMP processing techniques to maintain the regenerative properties of our AmNova amniotic membrane allografts. AmNova contains active proteins with anti-inflammatory and antibacterial properties, while the preserved extracellular matrix serves as a scaffold for tissue repair and regeneration. Our product candidate is currently in clinical studies.
OUR COMMERCIAL PRODUCTS
Wound & Ocular Applications
Our cross-linked human amniotic membrane allograft has the stringent quality controls to deliver the best patient outcomes. We use proprietary processing techniques to retain the native cytokines, growth factors, and collagen to support tissue healing and optimize antibacterial properties. Each AMS+ is shelf stable without refrigeration and ready to use for a range of wound care and ocular applications, without soaking or thawing. Available in dry or wet configurations and in different shapes and sizes.
Available for direct sale and partnership opportunities.
We are proud to partner with leading innovators, clinical researchers and investors to bring our proprietary regenerative technologies to patients.